Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > GP120 (HIV)

GP120 (HIV)

Brief Information

Name:HIV envelope protein gp120
Target Synonym:HIV Envelope Protein gp120
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:6
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
GP4-V15223 HIV HIV-1 [HIV-1/Clade E (CM244)] GP120 Protein, His Tag
GP4-V15223-structure
GP4-V15223-sds
GP4-V15223-elisa_1
GP5-V15224 HIV HIV-1 [HIV-1/Clade C (16055)] GP120 Protein, His Tag
GP5-V15224-structure
GP5-V15224-sds
GP5-V15224-elisa_1

Part of Bioactivity data

GP5-V15224-ELISA
HIV-1 [HIV-1/Clade C (16055)] GP120, His TagHIV-1 [HIV-1/Clade C (16055)] GP120, His Tag (Cat. No. GP5-V15224) ELISA bioactivity

Immobilized Human CD4, Fc Tag (Cat. No. CD4-H5259) at 2 μg/mL (100 μL/well) can bind HIV-1 [HIV-1/Clade C (16055)] GP120, His Tag (Cat. No. GP5-V15224) with a linear range of 0.5-63 ng/mL (QC tested).

GP4-V15223-ELISA
HIV-1 [HIV-1/Clade E (CM244)] GP120, His TagHIV-1 [HIV-1/Clade E (CM244)] GP120, His Tag (Cat. No. GP4-V15223) ELISA bioactivity

Immobilized Human CD4, Fc Tag (Cat. No. CD4-H5259) at 5 μg/mL (100 μL/well) can bind HIV-1 [HIV-1/Clade E (CM244)] GP120, His Tag (Cat. No. GP4-V15223) with a linear range of 20-156 ng/mL (QC tested).

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Radha-108 Approved Biomix Network Receptol HIV Infections Details
Fostemsavir Tromethamine 97IQ273H4L (UNII code); GSK 3684934; BMS-663068-03; BMS 626529 prodrug; BMS-663068; GSK-3684934A Approved Bristol-Myers Squibb Company Rukobia EU HIV Infections Viiv Healthcare Bv 2020-07-02 HIV Infections Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Microbicide monoclonal antibody triple combination (Polymun Scientific Immunobiologische Forschung) Phase 1 Clinical Polymun Scientific HIV Infections Details
Elipovimab GS-9722 Phase 1 Clinical Gilead HIV Infections Details
PDPHV-201401 PDPHV-201401 Phase 1 Clinical National Institute Of Allergy And Infectious Diseases (Niaid) HIV Infections Details
Suvizumab KD-247 Phase 1 Clinical Kaketsuken HIV Infections Details
A-1801 A-1801 Clinical Wuhan Bio-Raid Biotechnology HIV Infections Details
3BNC-117 GS-5423; 3BNC117-LS; 3BNC117 Phase 2 Clinical The Rockefeller University HIV Infections; Acquired Immunodeficiency Syndrome Details
GS-2872 10-1074; 10-1074-LS; GS-2872 Phase 2 Clinical The Rockefeller University HIV Infections Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message